BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17853310)

  • 1. Do utilization management controls for phototherapy increase the prescription of biologics?
    Simpson GL; Yelverton CB; Rittenberg S; Feldman SR
    J Dermatolog Treat; 2006; 17(6):359-61. PubMed ID: 17853310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
    Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
    Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
    Price J; Bhosle M; Feldman SR; Balkrishnan R
    J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phototherapy, psoriasis, and the age of biologics.
    Richard EG; Hönigsmann H
    Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
    Yelverton CB; Kulkarni AS; Balkrishnan R; Feldman SR
    Manag Care Interface; 2006 Jan; 19(1):33-6, 39. PubMed ID: 16453993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Care of patients with psoriasis: an audit of U.K. services in secondary care.
    Eedy DJ; Griffiths CE; Chalmers RJ; Ormerod AD; Smith CH; Barker JN; Potter J; Ingham J; Lowe D; Burge S
    Br J Dermatol; 2009 Mar; 160(3):557-64. PubMed ID: 19120330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease and treatment burden of psoriasis: examining the impact of biologics.
    Raval K; Lofland JH; Waters H; Piech CT
    J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and light therapies for the management of childhood psoriasis: part II.
    Cordoro KM
    Skin Therapy Lett; 2008 May; 13(4):1-3. PubMed ID: 18648714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of moderate-to-severe psoriasis treatment.
    Miller DW; Feldman SR
    Expert Opin Pharmacother; 2006 Feb; 7(2):157-67. PubMed ID: 16433581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and costs of severe psoriasis: the role of new biologics.
    Feldman SR; Pearce DJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into psoriasis management: commercial perspectives for the U.S. psoriasis market.
    Tran B; Feldman SR
    J Dermatolog Treat; 2011 Feb; 22(1):18-26. PubMed ID: 20528668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists.
    Koek MB; Buskens E; Bruijnzeel-Koomen CA; Sigurdsson V
    Br J Dermatol; 2006 Apr; 154(4):701-11. PubMed ID: 16536814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
    Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
    J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg.
    Yentzer BA; Feldman SR
    J Dermatolog Treat; 2011 Feb; 22(1):27-30. PubMed ID: 20524873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of home phototherapy.
    Rajpara AN; O'Neill JL; Nolan BV; Yentzer BA; Feldman SR
    Dermatol Online J; 2010 Dec; 16(12):2. PubMed ID: 21199628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
    Nast A; Reytan N; Rosumeck S; Erdmann R; Rzany B
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1337-42. PubMed ID: 18624864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis of the face and flexures.
    van de Kerkhof PC; Murphy GM; Austad J; Ljungberg A; Cambazard F; Duvold LB
    J Dermatolog Treat; 2007; 18(6):351-60. PubMed ID: 17907013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phototherapy in dermatology: A call for action.
    Lim HW; Silpa-archa N; Amadi U; Menter A; Van Voorhees AS; Lebwohl M
    J Am Acad Dermatol; 2015 Jun; 72(6):1078-80. PubMed ID: 25981004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.